Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Thorac Cardiovasc Surg. 2024 Jul;168(1):182-192.e1. doi: 10.1016/j.jtcvs.2023.10.041. Epub 2023 Oct 27.
Cardiovascular involvement in pediatric patients with connective tissue disease (CTD) is life-threatening, with aortic root dilatation being the most prevalent cardiovascular abnormality. We attempted to determine long-term outcomes of valve-sparing root replacement (VSRR) in this group, including cardiovascular reoperations for aortic aneurysm and dissection.
We conducted a retrospective analysis of pediatric patients with CTD who received VSRR in a single center from 2002 to 2021. The primary end point was a composite event of all-cause death and cardiovascular reoperations. The median follow-up duration was 8.3 years, with a maximum of 20.7 years.
The median age of 24 pediatric patients who had VSRR was 14.4 years. Marfan syndrome and Loeys-Dietz syndrome affected 19 (79.2%) and 5 (20.8%) patients, respectively. There was no early death. The 15-year survival rate was 91.7%. At 10 years after VSRR, the cumulative incidence of reoperation for aortic regurgitation was 15.6%, and for aortic aneurysm or dissection, it was 29.1%. The 10-year rate of freedom from the primary end point was 53.1%. The Cox multivariable analysis revealed younger age at surgery (hazard ratio, 1.279; 95% confidence interval, 1.086-1.505; P = .003) and VSRR before 13 years of age (hazard ratio, 5.005; 95% confidence interval, 1.146-21.850; P = .032) as independent prognostic factors for the primary endpoint.
VSRR for aortic root dilatation in pediatric patients with CTD demonstrated good long-term survival and low reoperation rates for aortic regurgitation. However, several patients developed later aortic aneurysm or dissection, and careful surveillance may be required, particularly in those who received VSRR at younger age.
心血管并发症是儿童结缔组织病(CTD)患者的生命威胁,其中主动脉根部扩张是最常见的心血管异常。我们试图确定这一组患者行保留瓣膜的主动脉根部替换术(VSRR)的长期结果,包括主动脉瘤和夹层的心血管再次手术。
我们对 2002 年至 2021 年期间在一家中心行 VSRR 的儿童 CTD 患者进行了回顾性分析。主要终点是全因死亡和心血管再次手术的复合事件。中位随访时间为 8.3 年,最长随访时间为 20.7 年。
24 例行 VSRR 的儿科患者的中位年龄为 14.4 岁。马凡综合征和 Loeys-Dietz 综合征分别影响 19 例(79.2%)和 5 例(20.8%)患者。无早期死亡。15 年生存率为 91.7%。VSRR 后 10 年,主动脉瓣反流再次手术的累积发生率为 15.6%,主动脉瘤或夹层的发生率为 29.1%。主要终点的 10 年无事件生存率为 53.1%。Cox 多变量分析显示,手术时年龄较小(风险比,1.279;95%置信区间,1.086-1.505;P=0.003)和 13 岁之前行 VSRR(风险比,5.005;95%置信区间,1.146-21.850;P=0.032)是主要终点的独立预后因素。
VSRR 治疗儿童 CTD 患者的主动脉根部扩张可获得良好的长期生存和较低的主动脉瓣反流再次手术率。然而,一些患者后来发生了主动脉瘤或夹层,需要进行仔细监测,特别是那些在较小年龄接受 VSRR 的患者。